Cissy M Kityo

10.9k citations

266 papers · 8.5k · 3 hit papers · h-index 47

Impact in

Infectious Diseases top 0.1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Tuberculosis Research and Epidemiology
- COVID-19 Clinical Research Studies
Virology top 0.5%
- HIV Research and Treatment

Papers in

Infectious Diseases 169
- HIV/AIDS drug development and treatment 95
- HIV/AIDS Research and Interventions 61
- Tuberculosis Research and Epidemiology 7
- COVID-19 Clinical Research Studies 3
Virology 24
- HIV Research and Treatment 24

Co-authors: Peter N. Mugyenyi (69 shared papers)Tobias F. Rinke de Wit (38 shared papers)Raph L Hamers (27 shared papers)Kim Sigaloff (27 shared papers)Roy D. Mugerwa (7 shared papers)Margaret Siwale (19 shared papers)David R. Bangsberg (4 shared papers)Kishor N. Mandaliya (18 shared papers)
Journals: Clinical Infectious Diseases (21 papers)AIDS (18 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (16 papers)PLoS ONE (14 papers)AIDS Research and Human Retroviruses (13 papers)
Partner nations: Uganda United States United Kingdom

In The Last Decade

Cissy M Kityo

254 papers receiving 8.3k citations

Cissy M Kityo's Hit Papers

align trajectories log scale

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial 2024 · 76 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2024 The Lancet Infectious Diseases
2021 Nature Medicine
2017 Nature Medicine

Peers

Countries citing papers authored by Cissy M Kityo

Since Specialization

Citations

This map shows the geographic impact of Cissy M Kityo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cissy M Kityo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cissy M Kityo more than expected).

Fields of papers citing papers by Cissy M Kityo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cissy M Kityo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cissy M Kityo. The network helps show where Cissy M Kityo may publish in the future.

Co-authors

The 25 scholars most cited alongside Cissy M Kityo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Cissy M Kityo Line = papers co-authored together Cissy M Kityo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 266 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Defining total-body AIDS-virus burden with implications for curative strategies Nature Medicine ·Jacob D. Estes, Cissy M Kityo, Francis Ntengereze Ssali, Louise A. Swainson, Krystelle Nganou‐Makamdop, Gregory Q. Del Prete, Steven G. Deeks, Paul A. Luciw Hit paper breakdown →	2017	342
2	A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus New England Journal of Medicine ·Christopher C. Whalen, John L. Johnson, Alphonse Okwera, David L. Hom, Robin E. Huebner, Peter N. Mugyenyi, Roy D. Mugerwa, Jerrold J. Ellner	1997	332
3	Depletion of Regulatory T Cells in HIV Infection Is Associated with Immune Activation The Journal of Immunology ·Mark P. Eggena, Banson John Barugahare, Norman G. Jones, Martin Okello, Steven Mutalya, Cissy M Kityo, Peter N. Mugyenyi, Huyen Cao	2005	314
4	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 Nature Medicine ·Steven G. Deeks, Nancie M. Archin, Paula M. Cannon, Simon Collins, Richard Brad Jones, Marein A.W.P. de Jong, Olivier Lambotte, Rosanne Lamplough Hit paper breakdown →	2021	263
5	HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study The Lancet Infectious Diseases ·Raph L Hamers, Carole Lorraine Wallis, Cissy M Kityo, Margaret Siwale, Kishor N. Mandaliya, Francesca Conradie, Mariëtte E. Botes, Maureen Wellington	2011	253
6	Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited Setting JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jessica H. Oyugi, Jayne Byakika-Tusiime, Edwin D. Charlebois, Cissy M Kityo, Roy D. Mugerwa, Peter N. Mugyenyi, David R. Bangsberg	2004	248
7	Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda AIDS ·Jessica H. Oyugi, Jayne Byakika-Tusiime, Kathleen E. Ragland, Oliver B Laeyendecker, Roy D. Mugerwa, Cissy M Kityo, Peter N. Mugyenyi, Thomas C. Quinn	2007	234
8	Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa New England Journal of Medicine ·Nicholas Iain Paton, Cissy M Kityo, Anne Hoppé, Andrew Reid, Andrew Ddungu Kambugu, Abbas Lugemwa, Joep J. van Oosterhout, Mary Kiconco	2014	176
9	Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study The Lancet Infectious Diseases ·Raph L Hamers, Rob Schuurman, Kim Sigaloff, Carole Lorraine Wallis, Cissy M Kityo, Margaret Siwale, Kishor N. Mandaliya, Prudence Ive	2011	170
10	Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa New England Journal of Medicine ·James Gita Hakim, Victor Musiime, Alexander J. Szubert, Jane Mallewa, Abraham Mosigisi Siika, Clara Agutu, Simon Mark Walker, Sarah Lilian Pett	2017	170
11	Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa JAIDS Journal of Acquired Immune Deficiency Syndromes ·Kim Sigaloff, Raph L Hamers, Carole Lorraine Wallis, Cissy M Kityo, Margaret Siwale, Prudence Ive, Mariëtte E. Botes, Kishor N. Mandaliya	2011	165
12	Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies Clinical Infectious Diseases ·Raph L Hamers, Kim Sigaloff, Annemarie M. J. Wensing, Carole Lorraine Wallis, Cissy M Kityo, Margaret Siwale, Kishor N. Mandaliya, Prudence Ive	2012	149
13	Severe Renal Dysfunction and Risk Factors Associated with Renal Impairment in HIV‐Infected Adults in Africa Initiating Antiretroviral Therapy Clinical Infectious Diseases ·Andrew Reid, Wolfgang Stöhr, Ann Sarah Walker, Ian G. Williams, Cissy M Kityo, Peter J. Hughes, Andrew Ddungu Kambugu, Charles F. Gilks	2008	135
14	Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults AIDS ·John L. Johnson, Alphonse Okwera, David L. Hom, Harriet Mayanja‐Kizza, Cissy M Kityo, Peter Nsubuga, Joseph G. Nakibali, Anita M. Loughlin	2001	126
15	Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV New England Journal of Medicine ·Nicholas Iain Paton, Joseph Musaazi, Cissy M Kityo, Stephen Walimbwa, Anne Hoppé, Apolo P. Balyegisawa, Arvind Kaimal, Grace Mirembe	2021	123
16	Excellent Adherence to Antiretrovirals in HIV+ Zambian Children Is Compromised by Disrupted Routine, HIV Nondisclosure, and Paradoxical Income Effects PLoS ONE ·Jessica Elizabeth Haberer, Adrian David Cook, Ann Sarah Walker, Marjorie Ngambi, Alex Ferrier, Veronica Mulenga, Cissy M Kityo, Margaret J. Thomason	2011	106
17	Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda HIV Medicine ·SR Penzak, Geoffrey Kabuye, Peter N. Mugyenyi, Frank Mbamanya, Ven Natarajan, RM Alfaro, Cissy M Kityo, Elizabeth Formentini	2007	104
18	Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial The Lancet HIV ·Nicholas Iain Paton, Joseph Musaazi, Cissy M Kityo, Stephen Walimbwa, Anne Hoppé, Apolo P. Balyegisawa, Jesca Asienzo, Arvind Kaimal	2022	99
19	Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children New England Journal of Medicine ·Anna Turkova, Ellen White, Cissy M Kityo, Tim Roy Cressey, Ebrahim Variava, Moherndran Archary, Grace Miriam Ahimbisibwe, Clare Shakeshaft	2021	93
20	A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial The Lancet. Gastroenterology & hepatology ·Sunil Suhas Solomon, Sandra Wagner Cardoso, Laura M Smeaton, Leonard Anang Sowah, Chanelle Wimbish, Gregory K. Robbins, Irena Brates, Christine Scello	2022	86

About Cissy M Kityo

Cissy M Kityo is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Epidemiology and Pharmacology, having authored 266 papers that have together received 8.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (95 papers), HIV/AIDS Research and Interventions (61 papers), HIV Research and Treatment (24 papers), HIV-related health complications and treatments (17 papers), Tuberculosis Research and Epidemiology (7 papers), Streptococcal Infections and Treatments (3 papers), COVID-19 Clinical Research Studies (3 papers) and Pneumonia and Respiratory Infections (3 papers). The work is most often cited by research in Infectious Diseases (5.1k citations), Virology (986 citations), Emergency Medicine (226 citations), Family Practice (26 citations) and Pharmacology (86 citations). Cissy M Kityo has collaborated with scholars based in Uganda, United States and United Kingdom. Frequent co-authors include Peter N. Mugyenyi, Tobias F. Rinke de Wit, Raph L Hamers, Kim Sigaloff, Roy D. Mugerwa, Margaret Siwale, David R. Bangsberg, Kishor N. Mandaliya, Wendy Susan Stevens and Ann Sarah Walker. Their work appears in journals such as Clinical Infectious Diseases, AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes, PLoS ONE and AIDS Research and Human Retroviruses.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Cissy M Kityo

Impact in

Papers in i

In The Last Decade

Cissy M Kityo

Cissy M Kityo's Hit Papers

Peers

Countries citing papers authored by Cissy M Kityo

Fields of papers citing papers by Cissy M Kityo

All Works

About Cissy M Kityo

Explore authors with similar magnitude of impact

Papers in